Trial Profile
A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2019
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Apr 2019 Results of the final anaysis (Cut-off date: 27 December 2013), published in the Japanese Journal of Clinical Oncology
- 07 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
- 27 Feb 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.